New hope for older adults with severe aplastic anemia: stem cell transplant breakthrough?
NCT ID NCT07586735
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests a new combination of drugs (BFCA regimen) given before a stem cell transplant from a half-matched donor. It aims to improve survival and reduce treatment failure in people aged 40 to 60 with severe aplastic anemia. The study will enroll 64 participants across multiple centers and follow their outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BUSULFAN 0.8 MG/KG/Q6H (DAYS -8 TO -7) FLUDARABINE 30MG/M2/DAY (DAYS -6 TO -2) CYCLOPHOSPHAMIDE 25 MG/KG/DAY AND R-ATG 2.5 MG/KG/DAY (DAYS -5 TO -2) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Universtiy Peoples' Hospital
Beijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.